Effect of Roflumilast combined with Budesonide on pulmonary function and inflammatory markers in patients with chronic bronchitis complicated with chronic obstructive pulmonary disease
10.13431/j.cnki.immunol.j.20250097
- VernacularTitle:罗氟司特联合布地奈德对慢性支气管炎合并慢性阻塞性肺疾病患者肺功能及炎症标志物的影响
- Author:
Han WANG
1
;
Bing HU
;
Zhixin ZHENG
Author Information
1. 南阳医学高等专科学校第一附属医院药学部,河南 南阳 473000
- Publication Type:Journal Article
- Keywords:
chronic bronchitis;
chronic obstructive pulmonary disease;
Roflumilast;
Budesonide;
forced vital capacity;
airway resistance;
interleukin-8;
oxidative stress
- From:
Immunological Journal
2025;41(10):696-702
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the effect of Roflumilast combined with Budesonide in the treatment of chronic bronchitis complicated with chronic obstructive pulmonary disease(COPD).Methods A total of 98 patients with chronic bronchitis complicated with COPD admitted from February 2023 to February 2025 were selected and divided into group A(n=49)and group B(n=49)by random number table method.Group A was given Budesonide,and group B was given Roflumilast combined with Budesonide.The clinical efficacy,symptom scores[Chronic Obstructive Pulmonary Disease Assessment Test(CAT),modified British medical research council(mMRC)],pulmonary function[forced vital capacity(FVC),peak exploratory flow(PEF),forced exploratory volume in one second(FEV1)],respiratory mechanics indexes[airway resistance(Raw),dynamic compliance(Cdyn),peak inspiratory pressure(PIP)],inflammatory factors[interleukin-8(IL-8),tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs-CRP)],oxidative stress markers[8-iso-prostaglandin F2α(8-iso-PGF2α),malondialdehyde(MDA),super oxide dismutase(SOD),glutathione peroxidase(GSH-Px)],adverse reactions and prognosis were compared between the two groups.Results The total effective rate of group B[95.92%(47/49)]was higher than that of group A[83.67%(41/49)](P<0.05).After treatment,CAT,mMRC score,PIP,Raw,8-iso-PGF2α,MDA,hs-CRP,TNF-α and IL-8 in group B were lower than those in group A,while FVC,PEF,FEV1,Cdyn,SOD and GSH-Px were higher than those in group A(P<0.01).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The number of acute exacerbation in group B was less than that in group A at 3 and 6 months after treatment(P<0.01).Conclusion The combination therapy of Roflumilast and Budesonide is significantly effective in the treatment of chronic bronchitis complicated with COPD.It can alleviate clinical symptoms,improve patients'pulmonary function and respiratory mechanics,inhibit inflammation and oxidative stress response,and has a favorable safety profile and good prognosis.
